Background Anaphylaxis, which is rare, has been reported after COVID‐19 vaccination, but its management is not standardized. Method Members of the European Network for Drug Allergy and the European Academy of Allergy and Clinical Immunology interested in drug allergy participated in an online questionnaire on pre‐vaccination screening and management of allergic reactions to COVID‐19 vaccines, and literature was analysed. Results No death due to anaphylaxis to COVID‐19 vaccines has been confirmed in scientific literature. Potential allergens, polyethylene glycol (PEG), polysorbate and tromethamine are excipients. The authors propose allergy evaluation of persons with the following histories: 1—anaphylaxis to injectable drug or vaccine containing PEG or derivatives; 2—anaphylaxis to oral/topical PEG containing products; 3—recurrent anaphylaxis of unknown cause; 4—suspected or confirmed allergy to any mRNA vaccine; and 5—confirmed allergy to PEG or derivatives. We recommend a prick‐to‐prick skin test with the left‐over solution in the suspected vaccine vial to avoid waste. Prick test panel should include PEG 4000 or 3500, PEG 2000 and polysorbate 80. The value of in vitro test is arguable. Conclusions These recommendations will lead to a better knowledge of the management and mechanisms involved in anaphylaxis to COVID‐19 vaccines and enable more people with history of allergy to be vaccinated.

No abstract

Introduction and objective Drugs are a frequent cause of severe anaphylactic reactions. Clinical epidemiology of drug-induced anaphylaxis (DIA) supports the identification of the most frequent eliciting drug groups, risk factors, symptoms and treatment procedures. Our aim was to analyze data to promote better recognition and long-term management of affected individuals. Methods Data from the European Anaphylaxis Registry (2007-2019) with 1,815 cases of drug-induced anaphylaxis were analyzed regarding demographics, elicitors, symptoms, comorbidities, and treatment. Results The most frequent eliciting groups of drugs were analgesics (41.27%) – with non-steroidal anti-inflammatory drugs (NSAIDs) being the most common subgroup (65.42%) – antibiotics (33.17%), local anesthetics (7.38%) and radiocontrast media (5.18%). Adrenaline was used more often in patients with DIA (23.20%) than in anaphylaxis due to other causes (17.82%). The majority of events occurred in female patients (65.34%), although they were admitted to hospital (29.01%) or an intensive care unit (ICU) (9.61%) less often. Skin symptoms were most common (84.02%), while gastrointestinal symptoms were reported less frequently (30.25%). Compared to other anaphylactic reactions in the registry (food/insects) severe reactions occurred significantly more often in DIA (5.62% vs. 1.67%). Hospitalization (31.63%) and ICU admission rates (11.85%) were significantly higher in DIA than anaphylactic reactions to other elicitors (27.58% and 5.45%). Conclusions DIA affects middle aged females more frequently and is more severe in elderly males in the sample observed. Analgesics and antibiotics are the leading causes of DIA. Adrenaline was rarely administered to patients, even though it is recommended by guidelines.